CareDx Inc

For the period ended Mar 31, 2024. Filed May 9, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 9, 2024

CDNA$80.77-4.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations for the Ended and

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	Three Months Ended March 31,
	2024	2023
Revenue:
Testing services revenue	$53,837	$61,784
Product revenue	8,594	6,861
Patient and digital solutions revenue	9,618	8,617
Total revenue	72,049	77,262
Operating expenses:
Cost of testing services	13,632	15,296
Cost of product	5,344	4,066
Cost of patient and digital solutions	6,958	6,604
Research and development	18,711	24,357
Sales and marketing	19,830	23,231
General and administrative	26,911	28,032
Total operating expenses	91,386	101,586
Loss from operations	(19,337)	(24,324)
Other income:
Interest income, net	2,885	2,666
Change in estimated fair value of common stock warrant liability	—	7
Other expense, net	(290)	(1,974)
Total other income	2,595	699
Loss before income taxes	(16,742)	(23,625)
Income tax benefit (expense)	83	(124)
Net loss	$(16,659)	$(23,749)
Net loss per share (Note 3):
Basic	$(0.32)	$(0.44)
Diluted	$(0.32)	$(0.44)
Weighted-average shares used to compute net loss per share:
Basic	51,692,358	53,643,216
Diluted	51,692,358	53,643,216

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.